Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 22Gastrointestinal 16CNS 16Genitourinary 11Head & Neck 6Dermatologic 5Other solid neoplasm 4Breast 4Sarcoma 2Gynecologic 2Tumor-Agnostic 1Lymphoid 1Endocrine 1

Conditions

Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Adrenal Gland Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5surufatinib 4gallium Ga 68 dotatate 4Nivolumab 4Cisplatin 4pembrolizumab 3atezolizumab 3Everolimus 3selpercatinib 2olaparib 2lanreotide 2avelumab 2Radiotherapy 2Paclitaxel 2Etoposide 23-Iodobenzylguanidine 2veliparib 1vandetanib 1tivozanib 1tislelizumab 1spartalizumab 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1pegfilgrastim 1irinotecan sucrosofate 1iodophenyl metomidate 1fosbretabulin 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Radiosurgery × Endocrine × Clear all
NCT04785287 2026-03-03

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
13 enrolled
EndocrineGastrointestinalThoracic

Adrenal Gland Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡